Arcutis Biotherapeutics, Inc. announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times more likely to achieve IGA Success with ZORYVE® topical foam, 0.3%, compared to vehicle i.
